De Vincentis A, Tavaglione F, Namba S, et al. Poor accuracy and sustainability of the first-step FIB4 EASL pathway for stratifying steatotic liver disease risk in the general population. Alimentary pharmacology & therapeutics. 2024. doi:10.1111/apt.17953
Hess A, Gentile SD, Ben Saad A, et al. Single-cell transcriptomics stratifies organoid models of metabolic dysfunction-associated steatotic liver disease. The EMBO journal. 2023;42(24):e113898. doi:10.15252/embj.2023113898